168 related articles for article (PubMed ID: 38105377)
1. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy.
Stoop TF; Seelen LWF; van 't Land FR; Lutchman KRD; van Dieren S; Lips DJ; van der Harst E; Kazemier G; Patijn GA; de Hingh IH; Wijsman JH; Erdmann JI; Festen S; Groot Koerkamp B; Mieog JSD; den Dulk M; Stommel MWJ; Busch OR; de Wilde RF; de Meijer VE; Te Riele W; Molenaar IQ; van Eijck CHJ; van Santvoort HC; Besselink MG;
Ann Surg Oncol; 2024 Apr; 31(4):2640-2653. PubMed ID: 38105377
[TBL] [Abstract][Full Text] [Related]
2. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis.
Brada LJH; Daamen LA; Magermans LG; Walma MS; Latifi D; van Dam RM; de Hingh IH; Liem MSL; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Nio YC; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Busch OR; Koerkamp BG; van Eijck C; Molenaar QI; Wilmink HJW; van Santvoort HC; Besselink MG;
Ann Surg; 2021 Nov; 274(5):729-735. PubMed ID: 34334641
[TBL] [Abstract][Full Text] [Related]
3. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
van Veldhuisen E; Klompmaker S; Janssen QP; Hilal MA; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Conlon KC; Frigerio IM; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Keck T; Kleeff J; Klaiber U; Labori KJ; Lesurtel M; Malleo G; Marino MV; Molenaar IQ; Mortensen MB; Nikov A; Pagnanelli M; Pandé R; Pfeiffer P; Pietrasz D; Rangelova E; Roberts KJ; Cunha AS; Salvia R; Strobel O; Tarvainen T; Wilmink JW; Koerkamp BG; Besselink MG;
Ann Surg Oncol; 2023 Mar; 30(3):1463-1473. PubMed ID: 36539580
[TBL] [Abstract][Full Text] [Related]
4. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
[TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Vogel JA; Rombouts SJ; de Rooij T; van Delden OM; Dijkgraaf MG; van Gulik TM; van Hooft JE; van Laarhoven HW; Martin RC; Schoorlemmer A; Wilmink JW; van Lienden KP; Busch OR; Besselink MG
Ann Surg Oncol; 2017 Sep; 24(9):2734-2743. PubMed ID: 28560601
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Walma MS; Brada LJ; Patuleia SIS; Blomjous JG; Bollen TL; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam R; Festen S; Jan de Groot D; Willem de Groot J; Mohammad NH; Hermans JJ; de Hingh IH; Kerver ED; van Leeuwen MS; van der Leij C; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nederend J; Nio CY; Patijn GA; Polée MB; Pruijt JF; Renken NS; Rombouts SJ; Schouten TJ; Stommel MWJ; Verweij ME; de Vos-Geelen J; de Vries JJJ; Vulink A; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):699-707. PubMed ID: 33280952
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
8. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T
Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009
[TBL] [Abstract][Full Text] [Related]
11. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
13. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study.
Seelen LWF; Doppenberg D; Stoop TF; Nagelhout A; Brada LJH; Bosscha K; Busch OR; Cirkel GA; den Dulk M; Daams F; van Dieren S; van Eijck CHJ; Festen S; Groot Koerkamp B; Haj Mohammad N; de Hingh IHJT; Lips DJ; Los M; de Meijer VE; Patijn GA; Polée MB; Stommel MWJ; Walma MS; de Wilde RF; Wilmink JW; Molenaar IQ; van Santvoort HC; Besselink MG;
Ann Surg; 2024 May; 279(5):832-841. PubMed ID: 37477009
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.
Lee J; Lee JC; Gromski MA; Kim HW; Kim J; Kim J; Hwang JH
Medicine (Baltimore); 2018 Dec; 97(50):e13592. PubMed ID: 30558029
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Eshmuminov D; Aminjonov B; Palm RF; Malleo G; Schmocker RK; Abdallah R; Yoo C; Shaib WL; Schneider MA; Rangelova E; Choi YJ; Kim H; Rose JB; Patel S; Wilson GC; Maloney S; Timmermann L; Sahora K; Rössler F; Lopez-Lopez V; Boyer E; Maggino L; Malinka T; Park JY; Katz MHG; Prakash L; Ahmad SA; Helton S; Jang JY; Hoffe SE; Salvia R; Taieb J; He J; Clavien PA; Held U; Lehmann K
Ann Surg Oncol; 2023 Jul; 30(7):4417-4428. PubMed ID: 37020094
[TBL] [Abstract][Full Text] [Related]
18. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis.
Tanaka M; Heckler M; Mihaljevic AL; Ei S; Klaiber U; Heger U; Büchler MW; Hackert T
Ann Surg Oncol; 2023 Apr; 30(4):2401-2408. PubMed ID: 36153440
[TBL] [Abstract][Full Text] [Related]
19. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
[TBL] [Abstract][Full Text] [Related]
20. Pancreatectomy After Neoadjuvant FOLFIRINOX Chemotherapy: Identifying Factors Predicting Long-Term Survival.
Addeo P; Averous G; de Mathelin P; Faitot F; Cusumano C; Paul C; Dufour P; Bachellier P
World J Surg; 2023 May; 47(5):1253-1262. PubMed ID: 36670291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
